NewAmsterdam Pharma Company N.V. Investing Cash Flow
NewAmsterdam Pharma Company N.V. (NAMS) reported Investing Cash Flow of -$16.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$4.76M.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$11.51M, a 503.12% decline year-over-year.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$21.14M.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $2.51M.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for fiscal 2025 was -$174.92M.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for fiscal 2024 was -$62.85M.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for fiscal 2023 was -$24.00K.
- NewAmsterdam Pharma Company N.V. net cash provided by (used in) investing activities for fiscal 2022 was -$221.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$16.27M 10-Q · filed 2026-08-05 | -$37.41M derived: sum of 3 quarters · filed 2026-08-05 | -$34.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.51M 10-Q · filed 2026-05-07 | -$32.65M derived: sum of 2 quarters · filed 2026-05-07 | -$30.14M derived: sum of 3 quarters · filed 2026-05-07 | -$189.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$21.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$18.64M derived: sum of 2 quarters · filed 2026-02-18 | -$177.77M derived: sum of 3 quarters · filed 2026-08-05 | -$174.92M 10-K · filed 2026-02-18 |
| 2025-09-30 | $2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$156.63M derived: sum of 2 quarters · filed 2026-08-05 | -$153.78M 10-Q · filed 2025-11-05 | -$215.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$159.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$156.28M 10-Q · filed 2026-08-05 | -$218.46M derived: sum of 3 quarters · filed 2026-08-05 | -$218.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.85M 10-Q · filed 2026-05-07 | -$59.32M derived: sum of 2 quarters · filed 2026-05-07 | -$59.40M derived: sum of 3 quarters · filed 2026-05-07 | -$59.61M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$62.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$62.25M derived: sum of 2 quarters · filed 2026-02-18 | -$62.46M derived: sum of 3 quarters · filed 2026-02-18 | -$62.85M 10-K · filed 2026-02-18 |
| 2024-09-30 | -$75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$284.00K derived: sum of 2 quarters · filed 2025-11-05 | -$669.00K 10-Q · filed 2025-11-05 | -$672.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$594.00K 10-Q · filed 2025-08-06 | -$597.00K derived: sum of 3 quarters · filed 2026-02-18 | -$606.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | -$385.00K 10-Q · filed 2025-05-08 | -$388.00K derived: sum of 2 quarters · filed 2026-02-18 | -$397.00K derived: sum of 3 quarters · filed 2026-02-18 | -$402.00K derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$12.00K derived: sum of 2 quarters · filed 2026-02-18 | -$17.00K derived: sum of 3 quarters · filed 2026-02-18 | -$24.00K 10-K · filed 2026-02-18 |
| 2023-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$14.00K derived: sum of 2 quarters · filed 2024-11-06 | -$21.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$12.00K 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$7.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$221.00K 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$24.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |